257 related articles for article (PubMed ID: 21419773)
1. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia.
Smith MA; Lew JB; Walker RJ; Brotherton JM; Nickson C; Canfell K
Vaccine; 2011 Nov; 29(48):9112-22. PubMed ID: 21419773
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of male HPV vaccination in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
[TBL] [Abstract][Full Text] [Related]
3. The predicted impact of vaccination on human papillomavirus infections in Australia.
Smith MA; Canfell K; Brotherton JM; Lew JB; Barnabas RV
Int J Cancer; 2008 Oct; 123(8):1854-63. PubMed ID: 18636563
[TBL] [Abstract][Full Text] [Related]
4. Prevention strategies against human papillomavirus in males.
Garland SM
Gynecol Oncol; 2010 May; 117(2 Suppl):S20-5. PubMed ID: 20138347
[TBL] [Abstract][Full Text] [Related]
5. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
Regan DG; Philp DJ; Hocking JS; Law MG
Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
[TBL] [Abstract][Full Text] [Related]
6. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia.
Gertig DM; Brotherton JM; Saville M
Sex Health; 2011 Jun; 8(2):171-8. PubMed ID: 21592430
[TBL] [Abstract][Full Text] [Related]
7. The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: a model-based analysis.
Malagón T; Joumier V; Boily MC; Van de Velde N; Drolet M; Brisson M
Vaccine; 2013 Mar; 31(13):1740-7. PubMed ID: 23384753
[TBL] [Abstract][Full Text] [Related]
8. Adolescent and young adult HPV vaccination in Australia: achievements and challenges.
Garland SM; Skinner SR; Brotherton JM
Prev Med; 2011 Oct; 53 Suppl 1():S29-35. PubMed ID: 21962468
[TBL] [Abstract][Full Text] [Related]
9. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.
Bogaards JA; Coupé VM; Meijer CJ; Berkhof J
Vaccine; 2011 Nov; 29(48):8929-36. PubMed ID: 21945961
[TBL] [Abstract][Full Text] [Related]
10. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
[TBL] [Abstract][Full Text] [Related]
11. Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program Register.
Brotherton J; Gertig D; Chappell G; Rowlands L; Saville M
Commun Dis Intell Q Rep; 2011 Jun; 35(2):197-201. PubMed ID: 22010515
[TBL] [Abstract][Full Text] [Related]
12. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
Gauthier A; Martín-Escudero V; Moore L; Ferko N; de Sanjosé S; Pérez-Escolano I; Catalá-López F; Ferrer E; Bosch FX
Eur J Public Health; 2008 Dec; 18(6):674-80. PubMed ID: 18641420
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
[TBL] [Abstract][Full Text] [Related]
14. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
[TBL] [Abstract][Full Text] [Related]
15. Knowledge of human papillomavirus (HPV) and the HPV vaccine in a national sample of Australian men and women.
Pitts MK; Heywood W; Ryall R; Smith AM; Shelley JM; Richters J; Simpson JM
Sex Health; 2010 Sep; 7(3):299-303. PubMed ID: 20719218
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention.
Garland SM; Brotherton JM; Skinner SR; Pitts M; Saville M; Mola G; Jones RW
Vaccine; 2008 Aug; 26 Suppl 12():M80-8. PubMed ID: 18945417
[TBL] [Abstract][Full Text] [Related]
17. Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries.
Baussano I; Lazzarato F; Ronco G; Dillner J; Franceschi S
Int J Cancer; 2013 Oct; 133(8):1876-81. PubMed ID: 23564420
[TBL] [Abstract][Full Text] [Related]
18. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
19. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark.
Olsen J; Jepsen MR
Int J Technol Assess Health Care; 2010 Apr; 26(2):183-91. PubMed ID: 20392322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
